Low Caffeine Administration first

PreclinicalSmall molecule

SState University of New York at Buffalo

Low Caffeine Administration first is one of 28 small molecule programs targeting Adolescent. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdolescentCompleted

AdolescentPreclinical

Completed

Competition

Competitive Landscape

32 competitors in Adolescent

#DrugCompanyPhaseTrials

Zoloft

VViatris Specialty LLC

Approved

4 2

Fanapt

VVanda Pharmaceuticals

Approved

2 3

Abilify

Otsuka

Approved

2 4

Sunlenca

Gilead

Phase 3

2 5

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

8 6

Lithobid

SSolvay Pharmaceuticals

Phase 3

2 7

Brintellix

Takeda

Phase 2

1 8

Camptosar

Pfizer

Phase 2

1 9

Cymbalta

Jazz Pharmaceuticals

Phase 2

1 10

Valdoxan

Novartis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adolescent1 trial

Gender Difference in Response to Caffeine in Children and Adolescents

Completed·SState University of New York at Buffalo·N/A·NCT02119416·101 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Low Caffeine Administration first. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Low Caffeine Administration first compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Low Caffeine Administration first. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — State University of New York at Buffalo company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SState University of New York at Buffalo

Low Caffeine Administration first

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Adolescent1 trial

References

Drug Info

Quick Facts

Related News